# Monoclonal Antibody Therapy in Treating Patients With Primary Myelodysplastic Syndrome

> **NCT00003984** · PHASE2 · WITHDRAWN · sponsor: **European Organisation for Research and Treatment of Cancer - EORTC**

## Conditions studied

- Myelodysplastic Syndromes

## Interventions

- **BIOLOGICAL:** lintuzumab

## Key facts

- **NCT ID:** NCT00003984
- **Lead sponsor:** European Organisation for Research and Treatment of Cancer - EORTC
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 1999-02
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2012-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003984, "Monoclonal Antibody Therapy in Treating Patients With Primary Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00003984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*